Diabetic Retinopathy and VEGF

N Gupta1, S Mansoor1, 2, A Sharma1, 3, A Sapkal1, J Sheth3, P Falatoonzadeh1, BD Kuppermann1, MC Kenney*, 1
1 Gavin Herbert Eye Institute, University of California, Irvine, USA
2 Department of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, USA
3 Department of Ophthalmology, Lotus Eye Care Hospital, Coimbatore, TN, India

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 1721
Abstract HTML Views: 1296
PDF Downloads: 282
Total Views/Downloads: 3299
Unique Statistics:

Full-Text HTML Views: 579
Abstract HTML Views: 499
PDF Downloads: 220
Total Views/Downloads: 1298

© Gupta et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Gavin Herbert Eye Institute 843 Health Sciences Road, Hewitt Hall, Room 2028, University of California Irvine, Irvine, CA 92679, USA; Tel: (949) 824-7603; Fax: (949) 824-9626; E-mail:


Diabetic retinopathy remains the leading vascular-associated cause of blindness throughout the world. Its treatment requires a multidisciplinary interventional approach at both systemic and local levels. Current management includes laser photocoagulation, intravitreal steroids, and anti-vascular endothelial growth factor (VEGF) treatment along with systemic blood sugar control. Anti-VEGF therapies, which are less destructive and safer than laser treatments, are being explored as primary therapy for the management of vision-threatening complications of diabetic retinopathy such as diabetic macular edema (DME). This review provides comprehensive information related to VEGF and describes its role in the pathogenesis of diabetic retinopathy, and in addition, examines the mechanisms of action for different antiangiogenic agents in relation to the management of this disease. Medline (Pubmed) searches were carried out with keywords “VEGF”, “diabetic retinopathy”, and “diabetes” without any year limitation to review relevant manuscripts used for this article.

Keywords: Diabetic retinopathy, VEGF, DME, diabetes, central retinal vein occlusion, PGF.


Diabetic retinopathy (DR), a well-known consequence of long-standing and poorly controlled diabetes mellitus (DM), causes significant vision loss and blindness in the human population. DR currently affects approximately 150 million people worldwide, and the World Health Organization projects that the number of people affected will double by the year 2025 [1].

In patients with DM, the prevalence of any form of diabetic retinopathy is approximately 24% [2]. Diabetic macular edema (DME) is the major vision-threatening complication of DR. The Wisconsin Epidemiologic Study has reported that the prevalence of DME in diabetics of 15-year duration is approximately 20% in patients with Type 1 DM and 25% in patients with Type II DM that are on treatment [3]. Patients without macular edema can still maintain good vision even if they have advanced stages of the disease. Therefore, management of DME has become crucial for ophthalmologists in preventing vision loss to their diabetic patients.

Macular edema is diagnosed clinically by documenting retinal thickening and/or hard exudates using biomicroscopic examination. The Early Treatment Diabetic Retinopathy Study (ETDRS) has described a specific type of DME called “Clinically Significant Macular Edema” (CSME) for which laser treatment is indicated [4]. Based on angiographic findings, diabetic maculopathy has been classified as either focal or diffuse, and ischemic or non-ischemic. Diabetic maculopathy caused by leaking microaneurysms is classified as focal, while leakage at the level of the capillary beds leads to diffuse. The visual prognosis for patients with the ischemic type is very poor as there is deprivation of blood to the retina in ischemic zones.

Diabetic retinopathy is a disease of the retina, but similar vascular and ischemic changes can be found in other parts of the eye in the more advanced stages. Profound ischemia of the retina leads to neovascularization (growth of new vessels) of the disc (NVD), the retina (NVE), the iris (NVI) and the angle (NVA). NVA can lead to neovascular glaucoma (secondary to closure of the angle). For many years these conditions have been treated by panretinal photocoagulation (PRP) of the retina, which causes regression of the abnormal new vessels on the iris and angle [5]. In advanced cases of neovascular glaucoma where there is synechial closure of the angle, a surgical shunt such as a Baerveldt tube shunt or Ahmed glaucoma valve must be placed to facilitate aqueous drainage. Currently, anti-VEGF drugs are being investigated for the treatment of rubeosis. The RAVE (Rubeosis Anti-VEGF) clinical trial for Ischemic Central Retinal Vein Occlusion (CRVO) utilizes monthly ranibizumab injections for nine months to determine if this treatment can prevent the development of neovascular glaucoma in eyes with CRVO.


Intensive glycemic control is one of the two important ways to reduce the risk of vision loss from DME. The Diabetes Control and Complications Trial [6] and UK Prospective Diabetes Study [7] showed that intensive blood glucose control reduced the risk of development of DME by 23%.

Laser photocoagulation is the second most important course of action to prevent vision loss from DME. Clinical trials such as the Diabetic Retinopathy Study (DRS) and ETDRS have shown that timely laser intervention can reduce the loss of vision by 90% [8, 9]. For proliferative diabetic retinopathy, PRP laser is the treatment of choice as demonstrated in several clinical trials. Unfortunately, the areas of retina treated with PRP laser exhibit scarring and loss of function.

In eyes of patients with DME, corticosteroids inhibit the expression of VEGF and decrease angiogenesis [10]. Platelet-derived growth factor (PDGF) is a proinflammatory cytokine that induces the expression of the VEGF gene, an effect that is downregulated by corticosteroids [11]. Intravitreal injections of triamcinolone acetonide (IVTA) are now commonplace and widely used for treatment of retinal disorders. In spite of being a fairly safe procedure, intravitreal steroid injections carry an inherent risk of major complications such as cataract, glaucoma, endophthalmitis (both infective and sterile), vitreous hemorrhage, and retinal detachment.

Visual outcomes are generally poor in advanced cases of DR with complications such as long-standing vitreous hemorrhage (VH), tractional retinal detachments (TRD), and fibrovascular proliferation. In these instances, the surgical approach is the procedure of choice [12]. The Diabetic Retinopathy Vitrectomy Study (DRVS) was a National Eye Institute sponsored, multicenter clinical trial program that established treatment guidelines for patients with advanced proliferative diabetic retinopathy. After four years of follow-up, the conclusions were that an early vitrectomy provided a greater chance for prompt visual recovery in eyes with recent severe vitreous hemorrhage.

Despite the presence of varied therapeutic modalities, vision loss occurs at an alarming rate due to DME. The ETDRS showed that despite laser treatment, 12% of subjects continued to have moderate visual loss. In addition, laser treatment is a destructive procedure that does not take into account the pathophysiology of DR and can cause tissue damage itself.

Recently, interest has developed regarding use of anti-VEGF in cases of DME. Although adverse effects such as nonfatal cerebrovascular accidents and myocardial infarction have been described [13], anti-VEGF agents are proving to be far superior to the laser treatments which are associated with extensive resultant tissue damage. The incidence of complications such as glaucoma and cataract encountered with the intravitreal injections of corticosteroids can be avoided with the use of anti-VEGF. For these reasons, they are becoming the preferred choice of treatment in cases of DME with coexisting glaucoma and in cases recalcitrant to lasers and intravitreal steroids.

Diabetic patients with concomitant hypertension are at a higher risk of developing DME and DR. Moreover, the DR in these patients tends to progress much more rapidly [14, 15]. The renin-angiotensin-aldosterone system (RAAS), which regulates blood pressure and maintains water balance, has a direct connection to the pathologic microvascular changes occurring in DR [16]. Angiotensin II, the major bioactive product of the RAAS, acts as an endocrine, paracrine, and intracrine hormone, and is a powerful vasoconstrictor of arterioles. In vitro studies have shown that angiotensin II directly stimulates the secretion of VEGF in cultured smooth muscle cells [17] and in cardiac endothelial cells [18]. Therefore, constriction of the retinal microvasculature could result in local increased VEGF production within the retina, which in turn could lead to angiogenesis [17, 19]. The detailed pathway linking angiotensin II to increased synthesis of VEGF is yet to be elucidated, but hypoxia-inducible factor (HIF-1α) has been shown to be involved at the intracellular signaling pathway level.


In 1948, Isaac Michaelson proposed that in the development of pathological angiogenesis, a key event was the synthesis and release of a diffusible angiogenic factor called “Factor X” by the ischemic retina [20]. Later in 1971, Judah Folkman presented the idea of inhibiting angiogenesis as a means to treat cancer, which then led to the discovery of anti-angiogenic factors [21]. Nearly forty years passed before the originally proposed “Factor X” could be isolated and identified. In 1983, Senger, Dvorak and colleagues discovered a key mediator involved in angiogenesis to be a protein secreted from a guinea pig tumor cell line. It had a potent capacity to induce vascular leakage and was named vascular permeability factor (VPF) [22]. In 1989, Napoleone Ferrara and colleagues identified a molecule present in bovine pituitary follicular cells that promoted the proliferation of endothelial cells and called it vascular endothelial growth factor (VEGF) [23]. Subsequently, the cloning of VPF by Daniel Connelly et al. and VEGF by Ferrara et al. confirmed that the two factors were the same protein [24, 25]. In 1992, two independent studies demonstrated that hypoxia could upregulate VEGF expression [26, 27]. Evidence from clinical studies supported the critical role of VEGF in ocular neovascularization. It was demonstrated that vitreous samples of patients with active proliferative retinopathies associated with diabetes and venous occlusive disorders had elevated VEGF levels [28].


Vascular endothelial growth factors (VEGF) are a subfamily of growth factors that function as signaling proteins for both vasculogenesis (the de novo formation of the embryonic circulatory system) and angiogenesis (the growth of blood vessels from pre-existing vasculature). VEGF is secreted primarily from retinal pigmented epithelial cells, pericytes, astrocytes, müller cells, glial cells, and endothelial cells. VEGF has several members including VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth factor (PGF). VEGF-A is a 36-46 kDa glycosylated protein derived by alternate splicing of mRNA from a single, 8-exon VEGF gene [29]. VEGF-A is expressed as five mRNA splice variants – isoforms 121, 145, 165, 189, and 206, depending upon the number of amino acids present. Larger isoforms (isoforms 189 and 206) have increased heparin binding ability, which reflects their ability to bind to cell surfaces and basement membranes. Unfortunately, the larger isoforms also have limited or no diffusibility. Smaller isoforms (isoform 121 and 145) are readily diffusible but have limited heparin binding ability. Isoform 165 has intermediate levels of diffusibility and heparin binding. VEGF 165 is the principle isoform secreted, and is critical for both development and pathological angiogenesis [30]. The other VEGF members probably have a greater role to play in tumors and cancers than in DR [31].


VEGF production is induced in response to ischemia or hypoxia (Fig. 1). Tissue hypoxia leads to the production of a DNA binding protein called hypoxia-inducible factor 1 (HIF-1). HIF-1 is a heterodimeric, basic helix-loop-helix protein that consists of two subunits: the constitutively-expressed HIF-1 beta subunit and the growth factor regulated HIF-1 alpha subunit [32]. In addition to playing a crucial role in VEGF production, HIF-1 is also responsible for the upregulation of the human erythropoietin gene in hypoxic cells, which is another adaptation to tissue hypoxia [33]. HIF-1 binds to the VEGF gene and initiates the transcription process. This leads to the generation and accumulation of VEGF mRNA by both increased mRNA transcription and decreased mRNA degradation [34], eventually leading to the intracellular accumulation of VEGF molecules. A chaperone protein called ORP 150 (oxygen regulated protein) is responsible for the transfer of VEGF from the endoplasmic reticulum to Golgi bodies. The expression of ORP150 mRNA is also induced by hypoxia [35].

Fig. (1).

Flowchart of the VEGF cascade showing the molecular chain of events that occur after retinal tissue hypoxia culminating in angiogenesis.


All members of the VEGF family stimulate cellular responses by binding to tyrosine kinase receptors on the endothelial cell surface, causing them to dimerize and become activated through transphosphorylation. VEGF-A has two types of receptors: VEGF receptor 1 (VEGFR-1 or Flt-1) and 2 (VEGFR-2 or KDR). In humans, VEGFR-1 is a protein that is encoded by the Flt-1 gene [35] and VEGFR-2 is a kinase insert domain receptor (KDR, a type III receptor tyrosine kinase) that is encoded by the KDR gene [36]. VEGFR-2 seems to be the primary receptor that mediates almost all of the cellular responses to VEGF-A. The VEGF receptors have three parts: an extracellular portion consisting of seven similar immunoglobulin-like domains, a single transmembrane hydrophobic spanning region, and an intracellular portion containing a split tyrosine kinase domain [37]. When the VEGF molecule binds to the extracellular portion of the VEGF receptors, the intracellular portion causes phosphorylation of the tyrosine amino acid residues and a cellular signal is transduced. This transduction in turn induces a cascade of intracellular signaling pathways. One of the pathways induced within the cells by VEGF is the protein kinase C (PKC) pathway [38]. The other pathways contribute to angiogenesis by synthesis of nitric oxide and induction of cellular proliferation.


VEGF is an important factor in the development of both proliferative DR and DME [39], altering retinal capillary permeability by increasing the phosphorylation of proteins involved with tight-junctions such as zonula occludens [40]. The VEGF induction activates mitogen-activated protein (MAP), resulting in endothelial cell proliferation. This cascade coincides with the activation of the phophatidylinositol 3-kinase (PI3)/Akt pathway after VEGFR-2 induction [33]. VEGF-A stimulates endothelial cells to release matrix metalloproteinases (MMPs) and urokinase-type plasminogen activator, resulting in the degradation of basement membranes and making cell migration possible. The activated endothelial cells express integrins such as αvβ3 and αvβ5, which aid in the migration through the degraded matrix [41]. Proliferation and migration of endothelial cells is followed by synthesis of basement membranes for the newly formed capillaries. The stability of these capillaries is achieved by recruitment of pericytes and smooth muscle cells that are regulated by platelet-derived growth factor (PDGF) [42].


Much work has been done to study the mechanisms of VEGF in hopes of reducing neovascularization and vessel leakage by blocking its effects. Fig. (1) shows the sites of action of the drugs that target abnormal neovascularization.

Anti-VEGF Antibodies:

Commercially, there are two drugs available in this class. Ranibizumab (Lucentis, Genentech Inc., San Francisco, CA) is a humanized monoclonal antibody fragment (Fab, fragment antigen-binding) retrieved from the parent molecule of bevacizumab (Avastin, Genentech Inc., San Francisco, CA) against VEGF-A [43].

Ranibizumab was designed for intra-ocular use as a smaller antibody fragment for better intraocular penetration into the retina. It was approved in 2006 by the US Food and Drug Administration (USFDA) to be used for intravitreal injections in the treatment of neovascular (wet) age-related macular degeneration (AMD). The treatment protocol most commonly followed is three intravitreal injections given at intervals of four weeks. The retina is then evaluated and the need for further treatment is determined based upon the status of neovascularization. Pilot studies with intravitreal ranibizumab have also shown decrease in mean retinal thickness and improved vision in patients with DME [44]. In three well designed, phase II or III trials (RESOLVE [45], RIDE and RISE [13], READ 2 [46, 47]), 1–2 year treatments with ranibizumab were found to be more effective than sham or focal/grid laser therapy in improving best corrected visual acuity (BCVA) and reducing macular thickness in patients with visual impairment associated with DME. Along with these studies, two other well designed phase III trials (RESTORE [48] and [49-52]) showed that one year of treatment with ranibizumab as an adjunct to laser therapy was more effective than laser therapy alone in improving BCVA and macular thickness in patients with visual impairment associated with DME. Ranibizumab alone or as an adjunct to laser therapy showed improvement at the first follow-up visits in these studies, and were associated with gains in vision-related quality of life, assessed using the National Eye Institute Visual Functioning Questionnaire-25. The ocular and non-ocular adverse events were similar to the patients with wet age-related macular degeneration or retinal vein occlusion that had received ranibizumab.

Bevacizumab (Avastin, Genentech Inc., San Francisco, CA) is a full length humanized monoclonal antibody against all isoforms of VEGF-A and binds to the VEGF molecule to prevent receptor binding. It has the USFDA approval for intravenous treatment for metastatic colon cancer. Although bevacizumab does not have USFDA approval for intravitreal use for ocular diseases, it has been used off label and is very effective in inhibiting neovascularization associated with various retinal proliferative vascular diseases such as CNV, proliferative diabetic retinopathy, neovascular glaucoma, diabetic macular edema, and macular edema secondary to retinal vein occlusions. The DRCR phase II showed a more favorable outcome for bevacizumab treated patients at three weeks compared to laser photocoagulation alone [53]. The BOLT study also favored bevacizumab over laser photocoagulation at one year [54, 55].

Inhibitors of Intracellular Transcription:

Bevasiranib (OPKO, FL, USA) is the first small interfering RNA (siRNA) drug designed to silence the genes that produce VEGF, which is largely believed to be responsible for causing DME. The RNAi assessment of bevasiranib in DME or RACE trials was a pilot phase II investigation of the safety and preliminary efficacy of the drug in patients with DME. This 48 patient, multicenter, double-masked, randomized trial studied 3 dose levels of bevasiranib, and showed a trend of decrease in macular thickness between weeks 8 and 12. In addition, higher dosages resulted in a larger reduction in thickness than the lowest dose [56].

Inhibitors of Extracellular VEGF:

Pegaptanib sodium (Macugen, Eyetech Pharmaceuticals Inc., New York, NY and Pfizer Inc., New York, NY), a RNA aptamer, was one of the earliest anti-VEGF drugs which the USFDA approved for the treatment of neovascular AMD. It binds and blocks isoform 165 of VEGF [57]. The Macugen Diabetic Retinopathy Study Group conducted a phase II randomized controlled trial of Pegaptanib for fovea-involving DME. After 36 weeks follow-up, the Pegaptanib-treated eyes had better visual acuity, more reduction in central retinal thickness, and less need for laser photocoagulation compared to the sham group. More recently, a phase II/III randomized controlled trial reported that Pegaptanib therapy was associated with improved visual outcomes in patients with DME for up to 2 years [58, 59].

Inhibitors of VEGF Receptor Expression:

Aflibercept (VEGF-Trap, Regeneron Pharmaceuticals Inc., Tarrytown, NY and the Sanofi-aventis Inc., Paris, France) is a total human recombinant fusion protein that binds with all forms of VEGF-A and placental growth factor (PGF) [60]. The Regeneron and Bayer Inc. (Leverkusen, Germany) companies are developing the drug for ocular use. The DA VINCI study showed favorable outcomes when compared to laser photocoagulation in cases of DME. The outcome of the VEGF Trap-Eye trial at the primary endpoint of 24 weeks, as well as through the 52 week follow-up period, showed statistically significant improvement in visual acuity with the agent. Additionally, reduction in the optical coherence tomography (OCT) retinal thickness was noted. At the end of 6 months, patient eyes treated with aflibercept showed a gain of 8.5 to 11.4 letters on average, compared with 2.5 letters for the laser treated group. Moreover, at the end of 52 weeks, aflibercept treated eyes gained 9.7 to 13.1 letters as compared with a one-letter loss for laser treated eyes. At the end of one year, 45% - 71% of patient eyes gained 10 letters or more, and 24% - 46% of eyes gained 15 letters or more. The visual improvement was accompanied with reduction of OCT retinal thickness and was well tolerated by the patients. Presently, a phase III randomized clinical trial is currently underway to investigate the efficacy of VEGF Trap-Eye therapy for diabetic macular edema [61,62].

Inhibitors of Intracellular Signaling Cascade Activating VEGF:

Midostaurin (PKC412, Fermentek Biotechnology, Jerusalem, Israel) is a potent inhibitor of multiple isoforms of protein kinase C (PKC), VEGF-R2, PDGFR (platelet-derived growth factor receptor), KIT tyrosine kinase (a receptor that binds stem cell factor) and Flt-3 tyrosine kinases [63]. Midostaurin blocks the VEGF receptor signaling and thereby prevents retinal neovascularization [64]. PKC 412 has shown inhibition of ischemia-induced neovascularization in an animal model [65], however, early pharmacodynamic studies have shown some adverse outcomes, specifically revealing its lack of specificity. The principle toxicities of PKC412 are nausea/vomiting and fatigue. The best tolerated dose was found to be 150mg/d for chronic administration [66]. Even at this dose it was hepatotoxic, thus shifting focus to a more selective drug, ruboxistaurin [67].

Protein Kinase C (PKC) Beta Inhibitor:

Ruboxistaurin (Eli Lilly and Co., Delaware, Indianapolis) is an orally administered PKC beta isoform-selective inhibitor. It is an investigational drug for the treatment of moderate to severe non-proliferative DR. The PKC-Diabetic Retinopathy Study (PKC-DRS) was formulated to evaluate the effect of ruboxistaurin on visual loss in patients with moderately severe to very severe non-proliferative DR. It showed a reduction in the incidence of both moderate visual loss (doubling of the visual angle) and sustained moderate visual loss (for 6 months). The PKC-DME Study (PKC-DMES) also indicated reduced progression of DME with ruboxistaurin, although this was a secondary endpoint. Ruboxistaurin has not yet received approval from the USFDA [68-71].


Laser photocoagulation still remains the gold standard treatment for proliferative DR and DME, but it is not effective in many patients. Recently, retina specialists are inclined to use anti-VEGF agents for the management of DME. Although only some of these drugs are FDA approved for intraocular use (i.e., ranibizumab, pegaptanib), many are currently being used off label in clinical practices (i.e., bevacizumab). These anti-VEGF drugs are used as adjunct therapies to laser treatment, but there is an increasing trend towards using them as primary treatment for diabetic macular edema.


The authors confirm that this article content has no conflict of interest.


This work was supported by Discovery Eye Foundation, Guenther Foundation, Iris and B. Gerald Cantor Foundation, Polly and Michael Smith Foundation, Lincy Foundation, Research To Prevent Blindness.


[1] King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections Diabetes Care 1998; 21(9): 1414-31.
[2] Heriot WJ, Borger JP, Zimmet P, King H, Taylor R, Raper LR. Diabetic retinopathy in a natural population Aust J Ophthalmol 1983; 11(3): 175-9.
[3] Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema Ophthalmology 1984; 91(12): 1464-74.
[4] Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Early treatment diabetic retinopathy study research group Arch Ophthalmol 1985; 103(12): 1796-806.
[5] Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy Am J Ophthalmol 2006; 142(1): 155-8.
[6] The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 1993; 329(14): 977-86.
[7] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 1998; 352(9131): 837-53.
[8] Landers MB, Stefansson E, Wolbarsht ML. Panretinal photocoagulation and retinal oxygenation Retina 1982; 2(3): 167-75.
[9] Castillejos-Rios D, Devenyi R, Moffat K, Yu E. Dye yellow vs argon green laser in panretinal photocoagulation for proliferative diabetic retinopathy: a comparison of minimum power requirements Can J Ophthalmol 1992; 27(5): 243-4.
[10] Nauck M, Roth M, Tamm M, et al. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids Am J Respir Cell Mol Biol 1997; 16(4): 398-406.
[11] Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells Eur J Pharmacol 1998; 341(2-3): 309-15.
[12] Bresnick GH, Myers FL. Vitrectomy surgery for diabetic retinopathy Annu Rev Med 1979; 30: 331-8.
[13] Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for Diabetic Macular Edema: Results from 2 Phase III Randomized Trials: RISE and RIDE Ophthalmology 2012. (Epub ahead of print): Available from:
[14] Marshall G, Garg SK, Jackson WE, Holmes DL, Chase HP. Factors influencing the onset and progression of diabetic retinopathy in subjects with insulin-dependent diabetes mellitus Ophthalmology 1993; 100(8): 1133-9.
[15] Lopes de Faria JM, Jalkh AE, Trempe CL, McMeel JW. Diabetic macular edema: risk factors and concomitants Acta Ophthalmol Scand 1999; 77(2): 170-5.
[16] Danser AH, van den Dorpel MA, Deinum J, et al. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy J Clin Endocrinol Metab 1989; 68(1): 160-7.
[17] Williams B, Baker AQ, Gallacher B, Lodwick D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells Hypertension 1995; 25(5): 913-7.
[18] Chua CC, Hamdy RC, Chua BH. Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells Biochim Biophys Acta 1998; 1401(2): 187-94.
[19] Funatsu H, Yamashita H, Ikeda T, Nakanishi Y, Kitano S, Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders Am J Ophthalmol 2002; 133(4): 537-43.
[20] Michaelson IC. The mode of development of the vascular system of the retina with some observations on its significance for certain retinal disorders Trans Ophthalmol Soc UK 1948; 68: 137-80.
[21] Folkman J. Tumor angiogenesis: therapeutic implications N Engl J Med 1971; 285: 1182-6.
[22] Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VA, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid Science 1983; 219: 983-5.
[23] Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells Biochem Biophys Res Commun 1989; 161: 851-.
[24] Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF Science 1989; 246: 1309-2.
[25] Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen Science 1989; 246: 1306-9.
[26] Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model Am J Pathol 1994; 145: 574-84.
[27] Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis Nature 1992; 359: 843-5.
[28] Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders N Engl J Med 1994; 331: 1480-7.
[29] Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor multiple protein forms are encoded through alternative exon splicing J Biol Chem 1991; 266(18): 11947-54.
[30] Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease Prog Retin Eye Res 2008; 27(4): 331-71.
[31] Olofsson B, Pajusola K, Kaipainen A, et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells Proc Natl Acad Sci USA 1996; 93(6): 2576-81.
[32] Semenza GL. HIF-1: using two hands to flip the angiogenic switch Cancer Metastasis Rev 2000; 19(1-2): 59-65.
[33] Ferrara N. Vascular endothelial growth factor: basic science and clinical progress Endocr Rev 2004; 25: 581-611.
[34] Levy AP, Levy NS, Goldberg MA. Post-transcriptional regulation of vascular endothelial growth factor: by hypoxia J Biol Chem 1996; 271(5): 2746-53.
[35] Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family Oncogene 1990; 5(4): 519-24.
[36] Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition Cell Signal 2007; 19(10): 2003-12.
[37] Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors Cancer Res 2000; 60(2): 203-12.
[38] Yoshiji H, Kuriyama S, Ways DK, et al. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis Cancer Res 1999; 59(17): 4413-8.
[39] Simo R, Hernandez C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy Diabetologia 2008; 51(9): 1574-80.
[40] Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors J Biol Chem 1999; 274(33): 23463-7.
[41] Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease Prog Retin Eye Res 2003; 22(1): 1-29.
[42] Crocker DJ, Murad TM, Geer JC. Role of the pericyte in wound healing: an ultrastructural study Exp Mol Pathol 1970; 13(1): 51-65.
[43] Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab fora treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study Ophthalmology 2006; 113(4): 633-4.: e1-4.
[44] Rodriguez-Fontal M, Alfaro V, Kerrison JB, Jablon EP. Ranibizumab for diabetic retinopathy Curr Diabetes Rev 2009; 5(1): 47-51.
[45] Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study Diabetes Care 2010; 33(11): 2399-405.
[46] Nguyen QD, Shah SM, Heier JS, et al. Primary end point (six months) results of the ranibizumab for edema of the mAcula in diabetes (READ-2) study Ophthalmology 2009; 116(11): 2175-81.
[47] Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study Ophthalmology 2010; 117(11): 2146-51.
[48] Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema Ophthalmology 2011; 118(4): 615-25.
[49] Diabetic Retinopathy Clinical Research Network: Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 2010; 117(6): 1064-77.
[50] Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 2011; 118(4): 609-14.
[51] Aiello LP, Beck RW, Bressler NM, et al. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema Ophthalmology 2011; 118(12): 5-14.
[52] Googe J, Brucker AJ, Bressler NM, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation Retina 2011; 31(6): 1009-27.
[53] Diabetic Retinopathy Clinical Research Network: A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema Ophthalmology 2007; 114: 1860-67.
[54] Michaelides M, Kaines A, Hamilton RD, et al. prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study). 12-month data: report 2 Ophthalmology 2010; 117(6): 1078-86.
[55] Michaelides M, Fraser-Bell S, Hamilton R, et al. Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study): report 1 Retina 2010; 30(5): 781-6.
[56] [Accessed May 15, 2012];
[57] Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration N Engl J Med 2004; 351(27): 2805-16.
[58] Cunningham ET, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema Ophthalmology 2005; 112(10): 1747-57.
[59] Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema Ophthalmology 2011; 118(6): 1107-8.
[60] Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap - Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye Drugs R D 2008; 9(4): 261-9.
[61] Do DV, Nguyen QD, Shah SM, et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema Br J Ophthalmol 2009; 93(2): 144-9.
[62] Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The da VINCI study: phase 2 primary results of VEGF trap-eye in patients with diabetic macular edema Ophthalmology 2011; 118(9): 1819-26.
[63] Fabbro D, Ruetz S, Bodis S, et al. PKC412--a protein kinase inhibitor with a broad therapeutic potential Anticancer Drug Des 2000; 15(1): 17-28.
[64] Wang Y, Yin OQ, Graf P, Kisicki JC, Schran H. Dose- and time-dependent pharmacokinetics of midostaurin in patients with diabetes mellitus J Clin Pharmacol 2008; 48(6): 763-5.
[65] Comer GM, Ciulla TA. Pharmacotherapy for diabetic retinopathy. Ocular manifestations of systemic disease Curr Opin Ophthalmol 2005; 15(6): 508-18.
[66] Propper DJ, McDonald A, Man P, et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C J Clin Oncol 2001; 19: 1485-92.
[67] Campochiaro1 PA and The C99-PKC412-003 Study Group. Reduction of Diabetic Macular Edema by Oral Administration of the Kinase Inhibitor PKC412 Invest Ophthalmol Vis Sci 2004; 45: 922-31.
[68] The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the protein kinase C 􀀁inhibitor diabetic retinopathy study (PKC-DRS) multicenter randomized clinical trial Diabetes 2005; 54(7): 2188-97.
[69] PKC-DRS2 Study Group. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy Ophthalmology 2006; 113(12): 2221-30.
[70] The PKC-DMES Study Group. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial Archiv Ophthalmol 2007; 125(3): 318-24.
[71] Aiello LP, Davis MD, Girach A, et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy Ophthalmology 2006; 113(12): 2221-30.